How to Help Your Patients Find Abrilada in Stock: A Provider's Guide

How to Help Your Patients Find Abrilada in Stock: A Provider's Guide

When a patient on Abrilada (Adalimumab-afzb) calls your office saying they can't get their medication, the clinical stakes are real. Gaps in adalimumab therapy can lead to disease flares, loss of drug efficacy due to anti-drug antibody formation, and increased healthcare utilization. As a prescriber, you play a central role in helping patients navigate the specialty pharmacy landscape and maintain uninterrupted treatment.

This guide provides actionable steps your practice can take to help patients locate Abrilada and avoid therapy disruptions.

Current Availability of Abrilada

Abrilada is manufactured by Pfizer and remains in active production. It is not in shortage as of early 2026. However, availability at any given specialty pharmacy depends on several factors:

• PBM formulary positioning: Each PBM selects preferred adalimumab biosimilars through competitive bidding. Abrilada may or may not be the preferred product on a given plan.
• Specialty pharmacy stocking: Most specialty pharmacies carry the biosimilars aligned with their primary PBM contracts. Pharmacies that primarily serve Express Scripts plans may stock different products than those serving CVS Caremark plans.
• Distribution channel: Abrilada flows through Pfizer's specialty distribution network. It is not typically stocked at retail pharmacy locations.

For an overview of why patients struggle to find Abrilada, see our provider shortage briefing.

Why Patients Can't Find Abrilada

Understanding the common barriers can help you anticipate and resolve access issues:

1. Wrong Pharmacy Type

Patients unfamiliar with specialty medications may try filling Abrilada at a retail pharmacy. They'll be told it's "not in stock" or "unavailable," which can feel like a shortage even though it isn't.

2. Formulary Misalignment

If you prescribe Abrilada but the patient's plan prefers a different biosimilar (e.g., Hadlima or Amjevita), the prescription may be rejected or subjected to a lengthy prior authorization process.

3. Prior Authorization Delays

PA turnaround times for biologics average 5 to 15 business days for initial approvals. During this time, patients have no access to their medication. Renewals can also cause gaps if not submitted proactively.

4. Specialty Pharmacy Onboarding

New patients starting Abrilada (or switching to it) must be onboarded with a specialty pharmacy. This involves benefits verification, PA processing, and patient enrollment — a process that can take 2 to 4 weeks.

5. Insurance Transition Periods

Patients who change jobs, age onto Medicare, or switch plans during open enrollment may temporarily lose coverage for their current biosimilar. These transition periods are high-risk for therapy gaps.

What Providers Can Do: 5 Steps

Step 1: Verify Formulary Coverage Before Prescribing

Before writing a prescription for Abrilada, check whether it's covered on the patient's plan. Many EHR systems now offer real-time benefit check (RTBC) tools that show formulary status, copay estimates, and PA requirements at the point of prescribing.

If Abrilada isn't preferred, consider prescribing the plan's preferred adalimumab biosimilar instead. All interchangeable biosimilars are clinically equivalent, so formulary alignment improves fill rates without compromising outcomes.

Step 2: Submit Prior Authorization Proactively

Don't wait for a rejection to trigger the PA process. Submit prior authorizations at the time of prescribing, especially for new starts and therapy switches. Use electronic prior authorization (ePA) where available — it can reduce turnaround from days to hours.

Ensure your clinical documentation includes:

• Diagnosis and disease severity
• Prior therapies tried and failed (for step therapy requirements)
• Reason for selecting Abrilada specifically (if applicable)

Step 3: Use Medfinder to Check Pharmacy Availability

Medfinder for Providers lets you and your staff quickly check which pharmacies have Abrilada in stock. This is especially useful when a patient's usual specialty pharmacy is out of stock or when you need to identify alternative pharmacies quickly.

Bookmark medfinder.com/providers for your care coordination team.

Step 4: Engage Pfizer enCompass Support

Pfizer's enCompass program provides dedicated support for both patients and providers:

• Benefits investigation: Determines patient-specific coverage for Abrilada
• Prior authorization support: Assists with PA submission and appeals
• Pharmacy coordination: Helps identify and connect patients with stocking pharmacies
• Co-pay assistance: Enrolls eligible commercially insured patients in co-pay programs ($0 copay for qualifying patients)

Provider line: 1-844-722-6672

Step 5: Establish a Bridge Plan for Therapy Gaps

When access issues arise, have a plan to prevent therapy interruptions:

• Samples: Keep Abrilada samples on hand when available from your Pfizer representative.
• Quick-switch protocol: Develop a practice protocol for switching between interchangeable biosimilars when formulary or availability issues arise.
• Patient communication: Proactively communicate with patients about the specialty pharmacy process, expected timelines, and who to call if there's a problem.

Alternatives to Abrilada

When Abrilada isn't accessible, the following interchangeable biosimilars can be prescribed as direct substitutes:

• Amjevita (Adalimumab-atto) — Amgen. Available in multiple dosage forms. Widely covered.
• Cyltezo (Adalimumab-adbm) — Boehringer Ingelheim. First interchangeable biosimilar approved.
• Hadlima (Adalimumab-bwwd) — Samsung Bioepis/Organon. Among the lowest WAC pricing (85% below Humira).
• Hyrimoz (Adalimumab-adaz) — Sandoz. Citrate-free formulation similar to Abrilada.

All carry interchangeable designations and are approved for the same indications. For more detail, see our alternatives guide.

Workflow Tips for Your Practice

• Designate a biologics coordinator. Assign a staff member to manage specialty pharmacy coordination, PA submissions, and patient follow-up for all biologic prescriptions.
• Build PA templates. Create prior authorization letter templates for common adalimumab indications to speed up the submission process.
• Track PA renewal dates. Set EHR reminders for PA renewal 30 days before expiration to prevent coverage lapses.
• Maintain a formulary reference. Keep an updated list of preferred biosimilars for the most common insurance plans in your patient population.
• Use Medfinder routinely. Incorporate medfinder.com/providers into your care coordination workflow to proactively check availability before prescribing.

Final Thoughts

Helping patients access Abrilada requires a proactive, systems-oriented approach. By verifying formulary coverage upfront, submitting PAs early, leveraging tools like Medfinder, and maintaining flexible prescribing protocols, your practice can minimize therapy disruptions and keep patients on track.

For additional provider resources, see our Abrilada shortage briefing for providers and guide to helping patients save money on Abrilada.